Osteotech has announced that it has completed enrollment for the clinical trial of DuraTech BioRegeneration Matrix. DuraTech, used to repair dura mater during cranial surgical procedures, is based
InteKrin has declared Phase 2a clinical study results at the American Diabetes Association annual meeting in New Orleans. The study demonstrated that once a day oral treatment with
Bio-Bridge Science has declared that its wholly-owned subsidiary, Bio-Bridge Science has entered into a joint venture contract with JR Scientific to form a new cell culture medium joint
Altus has initiated patient dosing in phase-II trial for ALTU-238 in growth hormone deficiency pediatric subjects. ALTU-238 is a long-acting, extended release formulation of recombinant human growth hormone.
AEterna Zentaris has initiated an extended study in the Phase-III program with cetrorelix pamoate, for the treatment of benign prostatic hyperplasia (BPH). Cetrorelix pamoate is currently in three
“Following the Annual General Meeting of the Company yesterday, the Board is pleased to recognize Livleen for her outstanding financial leadership in the first half of 2009,” said
Cannabis has announced that the Company has received its CAGE/NCAGE Code: 5FZM9 certification through Central Contracting Registration (CCR). Steve Kubby, President and CEO of Cannabis, said: “With this
Vitro declared that it has received US Patent number 7527971 entitled, “Generation and Differentiation of Adult Stem Cells.” The patent provides protection to a specific cell line derived
MDRNA announced that it has obtained full FDA approval of its Abbreviated New Drug Application (ANDA) for generic calcitonin-salmon nasal spray for the treatment of osteoporosis. Calcitonin-salmon nasal
Umicore and SiliCycle have entered into an exclusive sales representation agreement, under which SiliCycle will commercialize Umicore’ metalbased homogenous catalysts in the North American Life Science Industry. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.